Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY

Pitfalls of Insulin-like Growth Factor-I and Growth Hormone Assays

(2015) Riia K. Junnila et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels

(2014) Michael Droste et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist

(2012) M. Andreassen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

(2012) A. J. van der Lely et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy

(2009) Mónica Marazuela et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

ACROSTUDY: the first 5 years

(2009) Peter J Trainer   EUROPEAN JOURNAL OF ENDOCRINOLOGY